Traws Pharma holder Squadron exits 13G position
Traws Pharma, Inc. received an amended Schedule 13G filing (Amendment No. 4) from Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Traws Pharma, Inc. received an amended Schedule 13G filing (Amendment No. 4) from Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank. The group now reports beneficial ownership of 0 shares of Traws Pharma common stock, representing 0% of the class.
The filing states that each reporting person has no sole or shared voting power and no sole or shared dispositive power over any shares of Traws Pharma common stock, confirming that they collectively own 5 percent or less of the class.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Ownership of 5 percent or Less of a Class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Squadron Master Fund report in this Schedule 13G/A for TRAW?
Who are the reporting persons in the TRAW Schedule 13G/A Amendment No. 4?
What percentage of Traws Pharma (TRAW) does Squadron now own?
What does 'Ownership of 5 percent or less of a class' mean for TRAW here?
AI-generated analysis. How Rhea-AI works. Not financial advice.